Grace Therapeutics, Inc.
GRCE · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $11 | $0 | $0 |
| Gross Profit | $0 | -$11 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9,511 | $4,628 | $9,972 | $5,559 |
| G&A Expenses | $7,161 | $0 | $8,076 | $9,665 |
| SG&A Expenses | $7,161 | $6,673 | $8,212 | $9,781 |
| Sales & Mktg Exp. | $0 | $0 | $136 | $116 |
| Other Operating Expenses | $7 | $0 | $33,971 | $249 |
| Operating Expenses | $16,679 | $11,301 | $52,155 | $15,589 |
| Operating Income | -$16,679 | -$11,312 | -$52,155 | -$15,589 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,912 | -$3,318 | $184 | $5,122 |
| Pre-Tax Income | -$12,767 | -$14,630 | -$51,971 | -$10,467 |
| Tax Expense | -$3,199 | -$1,777 | -$9,542 | -$648 |
| Net Income | -$9,568 | -$12,853 | -$42,429 | -$9,819 |
| % Margin | – | – | – | – |
| EPS | -0.79 | -1.73 | -5.71 | -1.6 |
| % Growth | 54.3% | 69.7% | -256.9% | – |
| EPS Diluted | -0.79 | -1.73 | -5.71 | -1.6 |
| Weighted Avg Shares Out | 12,087 | 7,436 | 7,435 | 6,140 |
| Weighted Avg Shares Out Dil | 12,087 | 7,436 | 7,435 | 6,140 |
| Supplemental Information | – | – | – | – |
| Interest Income | $711 | $911 | $246 | $77 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $7 | $11 | $124 | $0 |
| EBITDA | -$16,672 | -$14,619 | -$18,123 | -$15,340 |
| % Margin | – | – | – | – |